ChiLob 7/4 is an intermediate CD40 agonist and chimeric IgG1, which was also shown to induce pro-inflammatory cytokines, with promising results in CD40-expressing solid tumors and diffuse large B-cell lymphoma resistant to conventional therapy in a phase I clinical trial [21] (NCT01561911, Table 1). This evidence concerns the gene CD40 and diffuse large B-cell lymphoma.